According to Drug and Therapeutics Bulletin (DTB), the testosterone patch, called Intrinsa, was recently licensed in the UK for the treatment of women who have gone through surgery-induced menopause and consequently experiencing lowered sex drive, a condition called hypoactive sexual desire disorder (HSDD) to be given along with estrogen replacement therapy. But it turns out there were some problems with the main trials on the patches.